Literature DB >> 30869825

Modifiable risk factors for cognitive impairment in Parkinson's disease: A systematic review and meta-analysis of prospective cohort studies.

Yu Guo1, Wei Xu1, Feng-Tao Liu2, Jie-Qiong Li1, Xi-Peng Cao1, Lan Tan1, Jian Wang2, Jin-Tai Yu2.   

Abstract

BACKGROUND: Cognitive impairment is a common and devastating manifestation in Parkinson's disease (PD). We aimed to identify modifiable risk factors for PD with cognitive impairment.
METHODS: We systematically searched PubMed and the Cochrane Library from June 1937 to September 2018 and included prospective cohort studies with random-effects model used to combine estimates. Primary analyses for all types of cognitive impairments and subgroup analyses for separate outcomes were conducted.
RESULTS: A total of 31,298 articles were identified, of which 32 articles with 18 factors met the inclusion criteria for meta-analysis. In the primary analysis, 9 modifiable risk factors were found to increase the risk of PD with cognitive impairment, including postural-instability-gait disorder (relative risk = 3.76, 95% confidence interval = 1.36-10.40), hallucinations (relative risk = 3.09, 95% confidence interval = 1.61-5.93), orthostatic hypotension (relative risk = 2.98, 95% confidence interval = 1.41-6.28), cerebrovascular disease (relative risk = 1.52, 95% confidence interval = 1.01-2.28), diabetes mellitus (relative risk = 1.47, 95% confidence interval = 1.13-1.92), obesity (relative risk = 1.38, 95% confidence interval = 1.15-1.65), cardiac disease (relative risk = 1.35, 95% confidence interval = 1.17-1.56), alcohol consumption (relative risk = 1.32, 95% confidence interval = 1.15-1.52), and smoking (relative risk = 1.31, 95% confidence interval = 1.14-1.50). In the subgroup analysis, postural-instability-gait disorder subtype, orthostatic hypotension and hallucinations may increase the risk of dementia in PD. A total of 37 articles were included in the systematic review, in which 9 risk factors and 1 protective factor were additionally associated in single studies with the risk of PD with cognitive impairment, and 5 factors were associated with specific cognition domains.
CONCLUSIONS: Effective interventions in the management of PD symptoms, comorbidities, and lifestyles may be promising to reduce PD with cognitive impairment risk.
© 2019 International Parkinson and Movement Disorder Society. © 2019 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; cognitive impairment; meta-analysis; modifiable risk factors

Mesh:

Year:  2019        PMID: 30869825     DOI: 10.1002/mds.27665

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  17 in total

1.  Effect of cerebral small vessel disease on cognitive impairment in Parkinson's disease.

Authors:  Yuan Shen; ZhiFeng Dong; JianGuo Zhong; PingLei Pan; Gang Xu; Zhiping Zhang; Xianxian Zhang; HaiCun Shi
Journal:  Acta Neurol Belg       Date:  2022-09-12       Impact factor: 2.471

2.  Modifiable Comorbidities Associated with Cognitive Decline in Parkinson's Disease.

Authors:  Emily Forbes; Thomas F Tropea; Sneha Mantri; Sharon X Xie; James F Morley
Journal:  Mov Disord Clin Pract       Date:  2021-01-20

Review 3.  The neuropsychiatry of Parkinson's disease: advances and challenges.

Authors:  Daniel Weintraub; Dag Aarsland; Kallol Ray Chaudhuri; Roseanne D Dobkin; Albert Fg Leentjens; Mayela Rodriguez-Violante; Anette Schrag
Journal:  Lancet Neurol       Date:  2022-01       Impact factor: 44.182

4.  The incidence, baseline predictors, and outcomes of dementia in an incident cohort of Parkinson's disease and controls.

Authors:  Carl Counsell; Cinzia Giuntoli; Qaisar Imran Khan; Jodi Maple-Grødem; Angus D Macleod
Journal:  J Neurol       Date:  2022-03-21       Impact factor: 6.682

5.  Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.

Authors:  Adeline Su Lyn Ng; Yi Jayne Tan; Alisa Cui Wen Yong; Seyed Ehsan Saffari; Zhonghao Lu; Ebonne Yulin Ng; Samuel Yong Ern Ng; Nicole Shuang Yu Chia; Xinyi Choi; Dede Heng; Shermyn Neo; Zheyu Xu; Nicole Chwee Har Keong; Kay Yaw Tay; Wing Lok Au; Louis Chew Seng Tan; Eng-King Tan
Journal:  Mol Neurodegener       Date:  2020-06-05       Impact factor: 14.195

Review 6.  Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors.

Authors:  Paulina Gonzalez-Latapi; Ece Bayram; Irene Litvan; Connie Marras
Journal:  Behav Sci (Basel)       Date:  2021-05-13

Review 7.  Approach to Cognitive Impairment in Parkinson's Disease.

Authors:  Qiang Zhang; Georgina M Aldridge; Nandakumar S Narayanan; Steven W Anderson; Ergun Y Uc
Journal:  Neurotherapeutics       Date:  2020-11-17       Impact factor: 6.088

Review 8.  Cognition Deficits in Parkinson's Disease: Mechanisms and Treatment.

Authors:  Congcong Fang; Longqin Lv; Shanping Mao; Huimin Dong; Baohui Liu
Journal:  Parkinsons Dis       Date:  2020-03-24

9.  Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.

Authors:  Chien-Tai Hong; Kai-Yun Chen; Weu Wang; Jing-Yuan Chiu; Dean Wu; Tsu-Yi Chao; Chaur-Jong Hu; Kai-Yin David Chau; Oluwaseun Adebayo Bamodu
Journal:  Cells       Date:  2020-03-17       Impact factor: 6.600

Review 10.  Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?

Authors:  Kathy Dujardin; Véronique Sgambato
Journal:  Front Neurosci       Date:  2020-01-29       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.